Samsung Biologics took part in DCAT Week 2026 held from March 23 to 27 in New York City, engaging with partners and industry peers.
Throughout the week, Samsung Biologics met with current and potential clients to discuss how its manufacturing and development capabilities can support a range of biopharmaceutical programs. These conversations centered on how the industry is adapting to increasing complexity in drug development, particularly as pipelines expand into more diverse and advanced modalities amid ongoing geopolitical uncertainty.
These themes were also reflected in the presentation at the DCAT Member Company Announcement Forum, where Kevin Sharp, Executive Vice President and Head of Sales and Operations, outlined Samsung Biologics’ approach to addressing industry needs.
The session explored how the company’s infrastructure and network design are evolving to support future demand. This includes preparations for Bio Campus III in Songdo, which is expected to support next-generation biopharmaceutical modalities, as well as the continued build-out of the company’s presence in the United States through the planned acquisition of a manufacturing facility in Rockville, Maryland, to enhance regional accessibility.
Sharp also emphasized the company’s continued collaboration as part of its broader approach to innovation. He introduced ongoing work with partners such as the Coalition for Epidemic Preparedness Innovations (CEPI) to support outbreak-ready vaccine manufacturing, and an initiative to establish a new Lilly Gateway Labs site in Korea, aimed at supporting emerging biotech companies at earlier stages of development.
Samsung Biologics’ ExellenS™ manufacturing framework was also introduced through on-site materials, providing an overview of the company’s approach to standardized processes, integrated systems, and scalable operations across its global manufacturing network.
Participation in DCAT Week provided an opportunity not only to share the company’s ongoing efforts but also to gain insights into how industry expectations are evolving. These insights continue to inform how Samsung Biologics approaches manufacturing, development, and partnership models going forward.
Samsung Biologics thanks all partners and stakeholders who engaged with the team during DCAT Week and looks forward to continuing these conversations.
Samsung Biologics took part in DCAT Week 2026 held from March 23 to 27 in New York City, engaging with partners and industry peers.
Throughout the week, Samsung Biologics met with current and potential clients to discuss how its manufacturing and development capabilities can support a range of biopharmaceutical programs. These conversations centered on how the industry is adapting to increasing complexity in drug development, particularly as pipelines expand into more diverse and advanced modalities amid ongoing geopolitical uncertainty.
These themes were also reflected in the presentation at the DCAT Member Company Announcement Forum, where Kevin Sharp, Executive Vice President and Head of Sales and Operations, outlined Samsung Biologics’ approach to addressing industry needs.
The session explored how the company’s infrastructure and network design are evolving to support future demand. This includes preparations for Bio Campus III in Songdo, which is expected to support next-generation biopharmaceutical modalities, as well as the continued build-out of the company’s presence in the United States through the planned acquisition of a manufacturing facility in Rockville, Maryland, to enhance regional accessibility.
Sharp also emphasized the company’s continued collaboration as part of its broader approach to innovation. He introduced ongoing work with partners such as the Coalition for Epidemic Preparedness Innovations (CEPI) to support outbreak-ready vaccine manufacturing, and an initiative to establish a new Lilly Gateway Labs site in Korea, aimed at supporting emerging biotech companies at earlier stages of development.
Samsung Biologics’ ExellenS™ manufacturing framework was also introduced through on-site materials, providing an overview of the company’s approach to standardized processes, integrated systems, and scalable operations across its global manufacturing network.
Participation in DCAT Week provided an opportunity not only to share the company’s ongoing efforts but also to gain insights into how industry expectations are evolving. These insights continue to inform how Samsung Biologics approaches manufacturing, development, and partnership models going forward.
Samsung Biologics thanks all partners and stakeholders who engaged with the team during DCAT Week and looks forward to continuing these conversations.
Share article
Related Content